lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
fungitraxx
avimedical b.v. - itraconazole - antimycotics for systemisk bruk, triazole derivater, itrakonazol - avian - for behandling av aspergillosis og candidiasis i følgesvenn fugler,.
adport 1 mg
sandoz - københavn - takrolimusmonohydrat - kapsel, hard - 1 mg
adport 0.5 mg
sandoz - københavn - takrolimusmonohydrat - kapsel, hard - 0.5 mg
adport 5 mg
sandoz - københavn - takrolimusmonohydrat - kapsel, hard - 5 mg
clarithromycin teva 500 mg
teva sweden ab - klaritromycin - tablett, filmdrasjert - 500 mg
clarithromycin teva 250 mg
teva sweden ab - klaritromycin - tablett, filmdrasjert - 250 mg
tacni 5 mg
teva sweden ab - takrolimus - kapsel, hard - 5 mg
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
clarithromycin accord 500 mg
accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 500 mg